Interactive Dashboard

At a glance

The National Respiratory and Enteric Virus Surveillance System (NREVSS) is a laboratory-based system that monitors respiratory and enteric virus activity.

The National Respiratory and Enteric Virus Surveillance System (NREVSS)

Overview

The National Respiratory and Enteric Virus Surveillance System (NREVSS) monitors viral activity in the United States. In this surveillance system, participating U.S. laboratories voluntarily report weekly to CDC the total number of tests performed to detect these viruses and the total number of those tests that were positive. They also report the specimen type, collection location, and week of collection. NREVSS allows for timely analysis of data to monitor viral seasons and circulation patterns.

All data graphs on this site are updated weekly.

NREVSS Dashboard

  1. Select a View Information can be viewed as national data (all participating NREVSS laboratories) or filtered by HHS region, surveillance year, or virus. To view respiratory or enteric virus data, select the respective view.
  2. Select Virus Select one or more viruses.

How it's used

NREVSS was created in the 1980s to monitor seasonal trends in respiratory virus activity and was later expanded to include select enteric viruses. Influenza testing data reported to NREVSS is integrated with CDC Influenza Surveillance.

Each week, participating U.S. laboratories from university and community hospitals, state and county public health departments, and commercial entities voluntarily report:

  • the total number of tests performed
  • the test type used for detection
  • the number of those tests with positive results

Respiratory test results on the dashboard only include results from nucleic acid amplification tests (NAATs), also referred to as polymerase chain reaction (PCR) tests. CDC makes NREVSS data available through this website.

CDC also publishes periodic summaries and alerts based on NREVSS data in CDC's Morbidity and Mortality Weekly Report and other peer-reviewed journals.

NREVSS plays an important role in describing the temporal and geographic circulation patterns of respiratory and enteric viruses—including monitoring changes in the typical annual circulation patterns and identifying viral outbreaks. NREVSS is a relatively simple and practical surveillance system, gathering vital information that informs CDC's activities that treat, prevent, and control respiratory and enteric viral diseases.

Viruses monitored in NREVSS and key surveillance reports

The following viruses are monitored by NREVSS. Additionally, you may find key surveillance reports by virus.


Virus
Key Surveillance Report

SARS-CoV-2, the virus that causes COVID-19

12

Respiratory syncytial virus (RSV)

3456

Influenza viruses

FluView Interactive

Human parainfluenza viruses (PIV) (types 1, 2, 3, and 4)

78910

Human metapneumovirus (HMPV)

1112

Rhinovirus/enterovirus (RV/EV)

13

Respiratory adenoviruses

14

(types 299E, NL63, OC43, HKU1)

151617

Rotavirus

1819

Norovirus

N/A
Print
Content Source:
National Center for Immunization and Respiratory Diseases; Coronavirus and Other Respiratory Viruses Division
  1. CDC. ― United States, 2020–2023. MMWR 2023; 72:529–535.
  2. CDC. ― United States, May 11, 2023. MMWR 2023; 72:523–528.
  3. CDC. — United States, 2017–2023. MMWR 2023; 72:355–361.
  4. CDC. — United States, 2014–2017. MMWR 2018; 67:71–76.
  5. CDC. Update: Respiratory Virus Surveillance — United States, 1984. MMWR 1984; 33:11.
  6. MMWR Reports since 1984 on Respiratory Syncytial Virus Activity and Respiratory Syncytial Virus Surveillance are searchable here: Reports by Topic | MMWR (cdc.gov). Please note: Publications from 2016 are searchable under Reports by Topic. For those dating before 2016, they are searchable through .
  7. CDC. — United States, 2020–2021. MMWR 2021;70(29).
  8. DeGroote NP, Haynes AK, Taylor C, et al. , United States, 2011–2019. Journal of Clinical Virology. 2020; 124:104261.
  9. Abedi GR, Prill MM, Langley GE, et al. , 1998–2010. Journal of the Pediatric Infectious Diseases Society. 2014;5(1):7-13.
  10. Weinberg GA, Hall CB, Iwane MK, et al. . The Journal of Pediatrics. 2009;154(5):694-699.e1.
  11. Haynes AK, Fowlkes AL, Schneider E, Mutuc JD, Armstrong GL, Gerber SI. , 2008 to 2014. PEDIATRICS. 2016;137(5): e20152927-e20152927.
  12. Edwards KM, Zhu Y, Griffin MR, et al. . New England Journal of Medicine. 2013;368(7):633-643.
  13. CDC. — United States, July–September 2022. MMWR 2022; 71:1265–1270.
  14. CDC. Surveillance of Human Adenovirus Types and the Impact of the COVID-19 Pandemic on Reporting — United States, 2017–2023. MMWR 2024; 73:1136–1141.
  15. . Published online April 25, 2024:332-334.
  16. Killerby, ME, Biggs HM, Haynes A, et al. . J Clin Virol. 2018 April;101: 52-6
  17. Shah MM, Winn A, Dahl RM, et al. , United States, 2014–2021. Emerging Infectious Diseases. 2022;28(10):1970-1976.
  18. Burnett E, Parashar UD, Winn A, Tate JE. —United States, 2000–2021. The Journal of Infectious Diseases. 2022;226(6):967-974.
  19. CDC. — United States, 2000–2018. MMWR 2019; 68:539–543.